Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients

BACKGROUND: Tamoxifen is considered a prodrug of its active metabolite endoxifen, which is dependent on the CYP2D6 and CYP3A enzymes. Tamoxifen pharmacokinetic variability influences endoxifen exposure and, consequently, its clinical outcome. This study investigated the impact of hormonal status on...

Descripción completa

Detalles Bibliográficos
Autores principales: Ximenez, João Paulo Bianchi, de Andrade, Jurandyr Moreira, Marques, Maria Paula, Coelho, Eduardo Barbosa, Suarez-Kurtz, Guilherme, Lanchote, Vera Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921430/
https://www.ncbi.nlm.nih.gov/pubmed/31852530
http://dx.doi.org/10.1186/s40360-019-0358-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921430/
https://www.ncbi.nlm.nih.gov/pubmed/31852530
http://dx.doi.org/10.1186/s40360-019-0358-y

Ejemplares similares